This course is designed for Western Australian pharmacists and other health professionals who dispense opioid substitution treatment in the form of supervised methadone and buprenorphine doses and who supply depot buprenorphine formulations to medical centres and clinics.
This training is for currently authorised prescribers in the WA Community Program for Opioid Pharmacotherapy (CPOP). Upon successful completion of this training and assessment CPOP Prescribers will be recommended for approval to prescribe depot buprenorphine formulations.
Approval as a CPOP Prescriber is issued by Chief Delegate of the Medicines and Poisions Regulation Branch, WA Department of Health and all providers are required to operate in accordance with WA CPOP Policies and Procedures and all associated policies and guidelines.
These resources demonstrate the administration and regulatory requirements for approved sublingual buprenorphine formulations. See below for: links to the Australian Product Information and Consumer Medicine Information for comprehensive prescribing and administration requirements.
In Western Australia sublingual buprenorphine is dispensed through authorised pharmacies under the direction of a medical practitioner approved by WA Department of Health to prescribe as part of the Community Program for Opioid Pharmacotherapy (CPOP). Refer to the WA CPOP Policies,Procedures and Guidelines for comprehensive prescribing and dispensing requirements.
For further clinical information on CPOP contact CPOP Advice and Support (CAS) on 9442 5042.
These videos and resources demonstrate how to administer the two different CPOP approved depot buprenorphine products and provide links to the Australian Product Information and Consumer Medicine Information.
In Western Australia depot buprenorphine can only be administered by an authorised health professional (i.e. medical practitioner, pharmacist or nurse) under the direction of a health professional (i.e. medical practitioner or nurse practitioner) who has approval from the WA Department of Health to prescribe depot buprenorphine products through the Community Program for Opioid Pharmacotherapy (CPOP).
For further information on the appropriate administration of depot buprenorphine contact CPOP Advice and Support (CAS) on 9442 5042.